Andrew Witty - GlaxoSmithKline


Last quote by Andrew Witty

We have got a great history here – we have been here since 1948, fantastic workforce who have really done everything we have ever asked them to do in just a brilliant way. We have got the space to expand and we have got the technical skills here which we think are the hub of what we need to start up the new
share this quote
Jul 19 2017
Andrew Witty has been quoted 23 times. The two most recent articles where Andrew Witty has been quoted are GlaxoSmithKline and Gilead to face off at HIV meeting next week and GSK warns profits to be hit by generic drugs competition. Most recently, Andrew Witty was quoted as having said, “It has an extremely impressive resistance profile. It is not easy to beat ... in terms of the thing that really matters, I think that dolutegravir remains an extremely impressive molecule.”.
Automatically powered by Storyzy
Take our quote verification challenge and find out !

Andrew Witty quotes

Sep 19 2016

I'm not, for a second, going to sit here and defend any historical pricing

Sep 19 2016

[Drug] pricing always has to be taken in a very responsible mindset to get the balance right between access and reward for

Jul 27 2016

What's so exciting here is we've always thought of medicine as chemistry, but actually there's a great opportunity to talk about electrical medicine as a whole new world of potential

Apr 27 2016

When you combine Breo (GSK's newer asthma drug) with our established product, Advair, we have been able to essentially hold our position, despite all the pressure we have been under in that Advair marketplace. That's a huge improvement from the previous two

Apr 27 2016

In America alone, our HIV new products sold exactly the same amount as out Advair product in the U.S., so this shows you how quickly the replacement of Advair is taking

Apr 27 2016 - Vaccine

We think this is a strong solid quarter for the company, especially because we are seeing good, healthy performance across all three of our businesses – pharma, vaccine and

Mar 31 2016

We are trying to put together an approach which is right for the right stage of maturity of the

Mar 17 2016

By doing so we will strongly position GSK to achieve the medium-term outlook set out to investors last year and deliver a return to core earnings growth in

Jul 24 2015 - Vaccine

While RTS,S (Mosquirix) on its own is not the complete answer to malaria, its use alongside those interventions currently available such as bed nets and insecticides would provide a very meaningful contribution to controlling the impact of malaria on children in those African communities that need it the

Mar 02 2015

If you were asking that question today, based on everything I can see from an external environment, my recommendation would probably be not to change the status quo. But obviously at a different date in the future you may come to a different conclusion to that

Mar 02 2015

It would be extremely unwise to do anything in anticipation of that. The chances of us doing something in an accelerated time frame are, I think, extraordinarily

Apr 02 2014

We're taking a very long-term view. We think demand is going to grow up significantly, we think that it's probably not right or efficient for all of that demand to be imported, some of it will always have to be imported just like any other country in the world but there is a requirement for building up domestic capability, and we and they benefit of having that manufacturing capability on shore in the

No quotes...
More Andrew Witty quotes
|< <
> >|

Quotes by Andrew Witty

Quote Verifier
Check if the quote you read on social networks is authentic
This webpage has been created by a robot: errors and absent quotes cannot be totally avoided

Quote :

Mistake :

Comments :